Follow On & Major Capital raisings
(>£5m) per project
We can advise about multiple capital raising options, plus provide access to a suite of national and global sources of funding through access to our own comprehensive, proprietary database of investors.
The Harwell Campus management office can advise about multiple capital raising options, plus provide access to a suite of national and global sources of funding through access to our own comprehensive, proprietary database of investors. This database is not available to third parties. It covers not only VC’s but also corporate funds, family offices, hedge funds as well as mainstream institutional investors predominantly in the Technology, Media & Telecommunications and Life Science sectors. This covers $210bn of invested capital in the US and Europe, representing over 55,000 transactions across 12,000 companies and involving nearly 9,000 investors, from over 70 countries as non-domestic investors become ever more important.
Qualified as a Chartered Accountant with PWC and started his career in investment banking with Deutsche Bank (Morgan Grenfell). He advised some of the largest Life Science groups from the late 1980s and joined the board of Kleinwort Benson in 1990. From 1991 he was closely involved with the London Stock Exchange in creating the rules for research based companies to be listed in Europe. While Head of Healthcare at Dresdner Kleinwort Benson, the Bank held a dominant position in raising money for listed biotechs. Gordon went on to co-found its biotech venture capital business investing in many successful emerging companies including, inter alia; Actelion (mkt cap.~$10bn) and Crucell (sold to JNJ $2.4bn).
He has advised many major multinational pharmaceutical groups in Europe and the US on large cross-border M&A deals and financings most notably SmithKline Beecham ($13bn) and Aventis ($28bn). In 2000 he was invited by the former chairman of SmithKline Beecham to join Donaldson, Lufkin & Jenrette as Managing Director, Head of Healthcare investment banking in Europe, with a private equity focus.
Gordon holds his FCA registration through STJ Advisors, the leading independent equity capital markets adviser and maintains a broad global network of relationships across the healthcare sector, while also acting as a consultant internationally for several banks on M&A and Licensing deals as well as private & public financings in this and other science and business sectors.
Is a Director of the Harwell Science & Innovation Campus Limited Partnership, plus related companies. He is a qualified Member of the Royal Institution of Chartered Surveyors and is also Founder and Managing Director of Prorsus Ltd. As a property development specialist, Angus has directed the creation of over a million square feet of new accommodation.
In 2011 Prorsus established a consortium, alongside Gordon Duncan, which secured a contract to acquire Pfizer’s 3 million square feet R&D Campus in Kent. Angus and his businesses are now focused on providing real estate, marketing, networking and other support to organizations, people and places inside the UK Knowledge Economy.
Angus is a firm believer in the power of research and innovation to deliver improved health, economic and social wellbeing for current and future generations.
Gordon Duncan or Angus Horner via the Campus Management Office
+44 (0) 1235 250091
Angus and Gordon are Partners in Harwell Oxford Partners Limited and also shareholders in the Campus Partnership
We can advise about multiple capital raising options, plus provide access to a suite of national and global sources of funding through access to our own comprehensive, proprietary database of investors.Read more
Being at Harwell gives companies greater visibility to other relevant and overlapping technology work and also raises profile amongst prospective investor communities.Read more